The Company intends to appoint an advisory panel of individuals with particular expertise in the Life Sciences industry to support the Board’s identification, assessment and appraisal of potential investment opportunities and to provide general guidance to the Board where required. Such appointments will commence on Admission, and the individuals forming the Advisory Panel from Admission are as set out below.
Dr Stewart White
Chair of the Advisory Panel
and member of the Investment Committee
Stewart has recent and direct board experience of AIM quoted companies, most recently as founding CEO of Collagen Solutions plc. Current positions include Executive Chairman at Novel Technologies Holdings Limited, Chairman of The Electrospinning Company Limited, Non-Executive Director of CuanTec Limited and Visiting Professor (Technology Entrepreneurship – Biomedical Engineering) at the University of Glasgow. Stewart has 20 years’ experience in commercialisation, product development and manufacturing of medical devices, advanced biologics and active pharmaceutical ingredients. A graduate of the University of Strathclyde, Stewart holds a first class BSc (Hons) in Applied Microbiology and a Ph.D. in Bioprocessing and an MBA.
Ron is an experienced biosciences entrepreneur, whose early career was with The Wellcome Foundation Ltd, holding divisional director and managing director positions in the main Pharmaceutical Business and in the spin out of vaccines, veterinary and environmental health businesses. After 22 years with Wellcome, Ron joined Amersham International plc holding main board positions as commercial director, then Chief Executive Officer of Amersham Pharmacia Life Sciences and Executive Vice Chairman of Amersham plc. Following eleven years with Amersham, Ron went on to become the Chief Executive Officer or Chairman of several start up and turn around businesses, with successful exits between £60 million and £300 million. Ron is currently the Executive Chairman of Sky Medical Technologies Ltd, Executive Chairman of SVAR Life Sciences AB, Executive Chairman of Carus Ltd (Veterinary Innovation) and Non-Executive Chairman BAR Ltd.
Per was Chief Technology Officer at Thermo Fisher Scientific ImmunoDiagnostic Division (Phadia) has a Ph.D. in cell biology and more than 30 years of Life Science experience including, international industrial experiences in research and development, medical and regulatory affairs, intellectual property rights and business development, including strategy and mergers and acquisitions. After postdoctoral employment at Department of Laboratory Medicine, University of California, San Francisco, he was appointed as associate professor at Uppsala University and as associate professor at Swedish Agricultural University, Faculty of Veterinary Medicine. He has contributed to more than 100 scientific articles, abstracts, patents and congress presentations and served in a multitude of scientific organisations. Per’s main focus is on strategy, business development and innovation and, in 1990, he wrote an MBA thesis on management of innovation. Per’s experience include head of research and development (immunology) at Sanofi Diagnostics Pasteur Inc. and vice president of research and development at Pharmacia Diagnostics AB, with development and registration of diagnostic products throughout the world including Europe, US and Japan.
Alastair has been Chief Executive Officer of Avacta Group plc since its inception in 2005 and has been responsible for the management and strategic development of the company, having led the IPO in 2006 and subsequent fund-raising and mergers and acquisitions activities of the group, and has overseen the product development programmes. Alastair combines world-class scientific and technical knowledge with a highly commercial mindset. He has a degree and Ph.D. in Physics from the University of Manchester and, after working in the US for a period, took up a position at the University of Leeds in 1995. At the age of 38, he was awarded a Chair of Molecular Biophysics and had, over ten years, grown one of the leading biophysics research groups in Europe. He left his academic career in 2007 to focus full time on delivering value to Avacta shareholders.